Clinical trials: Persons With Psychiatric Disorders
Cognitive Decline, Cognitive Deficit
Validation Study SCOBES-AR
Purpose of the study The purpose of this study is to evaluate five tests to see if they are suitable for the early detection of cognitive impairment in people over the age of 60.
- Conditions
- Cognitive Decline, Cognitive Deficit, Cognitive Impairment
- Trial name
- NCT04204239
- Where
- Austria
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- FH Joanneum Gesellschaft mbH
Schizophrenia
A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.
A clinical study to evaluate the long-term safety and tolerability of an investigational drug in people with schizophrenia. This study is accepting male and female participants between 18 years old -65 years old who have been…
- Trial name
- NCT04115319
- Testing
- SEP363856, quetiapine XR
- Where
- 42 sites in United States, Romania and 2 more
- Volunteers
- 305 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Adults, Acute Stress Reaction
Impact of MetaCalm on Stress of Healthy People With Acute Stress
This Open-Label, Non-Randomized Clinical Study involving 280 participants who will undergo a total participation of 6 hours.
- Trial name
- NCT07507669
- Testing
- 2 chewable tablets of MetaCalm, 4 chewable tablets of MetaCalm
- Where
- Italy
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Metagenics, Inc.
Schizophrenia
A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication
This study evaluated how well SEP-363856 works and how safe it is in people with schizophrenia that switch to SEP-363856 from their current antipsychotic medication.
- Trial name
- NCT05628103
- Testing
- SEP-363856
- Where
- 25 sites in United States
- Volunteers
- 101 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Exploratory Study of a Digital Therapeutics in People With Schizophrenia
CT-155 is a novel prescription digital therapeutic (PDT) being developed by Click Therapeutics, Inc. (Click) and Boehringer Ingelheim (BI) using an interactive, software-based intervention to treat schizophrenia
- Trial name
- NCT05438160
- Testing
- Clinical Learning Study smartphone app (i.e., the study app)
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Click Therapeutics, Inc.
Parkinson Disease
A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's
A Phase 1, randomized, double-blind, placebo-controlled study of BMS-984923 administered orally twice daily (BID) for 28 days in participants with Parkinson's disease.
- Trial name
- NCT06309147
- Testing
- BMS-9894923
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Allyx Therapeutics
Depressive Disorder, Major
A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression
This study is open to adults with depression (major depressive disorder) for whom standard treatment with antidepressants alone does not work sufficiently.
- Trial name
- NCT04521478
- Testing
- BI 1358894, Quetiapine
- Where
- 120 sites in United States, Argentina and 12 more
- Volunteers
- 389 people
- Sponsor
- Boehringer Ingelheim
Posttraumatic Stress Disorder (PTSD)
Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people with chronic, treatment-resistant PTSD.
- Trial name
- NCT01689740
- Testing
- Full Dose MDMA-assisted therapy (125 mg), Open-Label Full Dose MDMA-assisted therapy (125 mg), Psychotherapy
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Resilient Pharmaceuticals
Cancer, Psycho-Oncology
What Impact Does an Initial Psycho-oncological Contact Have on People With Cancer?
When diagnosed with cancer, patients or their relatives may, if they wish, on the recommendation of the treatment team and/or in cases of high stress, seek psycho-oncological support.
- Trial name
- PICS (NCT07544446)
- Testing
- initial psycho-oncological contact, Standard
- Where
- 5 sites in Switzerland
- Volunteers
- 148 people
- Sponsor
- Lindenhofgruppe AG
ADHD, Hyperactivity
Treatment With Cannabis Oil Containing CBD, THC, CBDV or CBG vs. Placebo of Persons With ADHD
ADHD is the most frequent neuro-developmental disorder in childhood and often continues into adolescence and adulthood. Indicated drug treatments for ADHD fall into 2 categories: stimulants (such as methylphenidate and…
- Conditions
- ADHD, Hyperactivity, Attention Deficit
- Trial name
- NCT05219370
- Testing
- Cannabis oil
- Where
- Israel
- Volunteers
- 8 people
- Sponsor
- Brlev Agricultural Crops Ltd
Jet Lag Disorder, Jet Lag
A Study on the Effectiveness of a Dietary Supplement FitoAvia for Jet Lag
Purpose of the study: Evaluation of the effects of dietary supplement Fitoavia in people with dyssynchrony Objectives of the study: 1. Assessment of the condition of patients with jet lag of 4 hours or more 2.
- Conditions
- Jet Lag Disorder, Jet Lag, Jet Lag Type Insomnia, Cognition Improvement
- Trial name
- NCT07695870
- Testing
- Fitoavia, Questionnaire and Physical Exam, cognition tests
- Where
- Russia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- MiraxBioPharma
Abuse Prevention
Protect Yourself: Abuse Prevention for People With Intellectual Disabilities
The purpose of this study is to help individuals and their caregivers develop a plan on how to recognize, deal with and respond to abusive situations.
- Trial name
- AP4ID (NCT03998605)
- Testing
- Abuse Prevention Program, Control Condition
- Where
- United States
- Sponsor
- Double S Instructonal Systems
Borderline Personality Disorder
A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder
This study is open to adults with borderline personality disorder. The purpose of this study is to find out whether a medicine called BI 1358894 helps to reduce symptoms in people with borderline personality disorder.
- Trial name
- NCT04566601
- Testing
- BI 1358894
- Where
- 67 sites in United States, Argentina and 13 more
- Volunteers
- 390 people
- Sponsor
- Boehringer Ingelheim
Alzheimer Disease, Early Onset
Ryan Companion Robot for Assisting Elderly People With Alzheimer's Disease
The objective of this project is to conduct research and a pilot study to demonstrate the potential clinical impact and technical feasibility of a socially-assistive robot, called Ryan Companionbot (hereafter Ryan), for life…
- Trial name
- NCT05052866
- Testing
- Social Robot
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- DreamFace Technologies, LLC
Schizophrenia
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
A clinical trial to study the efficacy and safety of an investigational drug in acutely psychotic people with schizophrenia. Participants in the study will either receive the drug being studied or a placebo.
- Trial name
- NCT04092686
- Testing
- SEP-363856 75mg, SEP-363856 100mg
- Where
- 53 sites in United States, Bulgaria and 5 more
- Volunteers
- 464 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Narcolepsy
A Study to Collect Information of People With Narcolepsy in Spain
This study aims to review information of people with a sleep condition called narcolepsy. Narcolepsy is a condition that causes extreme sleepiness during the day including falling asleep suddenly.
- Trial name
- SOMNUS (NCT04667338)
- Where
- Spain
- Volunteers
- 214 people
- Sponsor
- Takeda
Major Depressive Disorder, Bipolar Disorder
Testing the Value of Smartphone Assessments of People With Mood Disorders
The purpose of this study is two-fold: 1. To identify the best smartphone data features (based on keyboard, sensor, voice/speech data) that correlate with mood, anxiety, and cognitive assessments in patients with Major Depressive…
- Trial name
- NCT03429361
- Testing
- Health by Mindstrong
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Mindstrong
Sleep Disorders, Circadian Rhythm, Cognitive Dysfunction
Feasibility Study on the Use of Redormin®500 on Day-time Cognition
Randomized, double-blind, parallel groups, placebo-controlled, baseline/run-in period of 21 days followed by trial period of 21 days, digital phenotyping (sleep, cognitive/psychological parameters and HRV).
- Trial name
- NCT05684523
- Testing
- Valerian-Hop Extract
- Where
- Switzerland
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Max Zeller Soehne AG
Borderline Personality Disorder, Attention Deficit Hyperactivity Disorder
A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder
This study is open to adults with certain mental health conditions. The purpose of this study is to find out how a medicine called BI 3031185 is tolerated by people with certain mental health conditions.
- Trial name
- NCT07001475
- Testing
- BI 3031185
- Where
- 7 sites in Germany
- Volunteers
- 78 people
- Sponsor
- Boehringer Ingelheim
Amyotrophic Lateral Sclerosis
A Second Intermediate-Size Expanded Access Protocol (EAP) for Pridopidine in People With Amyotrophic Lateral Sclerosis (Pridopidine EAP 2)
Protocol PL101-ALS501: This EAP will provide access to pridopidine for up to 200 patients with ALS who are ineligible for clinical trials.
- Trial name
- NCT06069934
- Testing
- Pridopidine
- Where
- 32 sites in United States, Puerto Rico
- Sponsor
- Prilenia